CJC-1295 Effect on IGF-1: Direction, Magnitude, Time Course, and Monitoring

What CJC-1295 Does to IGF-1 Levels

CJC-1295 raises IGF-1. It acts as a synthetic analogue of growth-hormone-releasing hormone (GHRH), binding GHRH receptors on pituitary somatotrophs and driving pulsatile GH release. The liver then converts the additional GH into IGF-1, which is the primary anabolic and regenerative mediator downstream. IGF-1, not GH itself, is the lab value clinicians track because it integrates GH exposure over days rather than reflecting a single, transient pulse.

The relationship is dose-dependent and formulation-dependent. Teichman et al. (2006) published the defining phase-II RCT in the Journal of Clinical Endocrinology and Metabolism, demonstrating that CJC-1295 with the drug-affinity complex (DAC) produced mean GH increases of 2- to 10-fold above baseline that persisted for 6 to 14 days after a single subcutaneous injection [1]. IGF-1 rose correspondingly and remained above baseline for the entire observation window. That single-dose durability is a pharmacokinetic signature of the DAC-conjugated form and has direct implications for how often patients inject and when labs should be drawn.

The GHRH Mechanism in Plain Terms

GHRH is a 44-amino-acid hypothalamic peptide with a plasma half-life of roughly 7 minutes in native form. CJC-1295 (modified GRF 1-29) retains the first 29 amino acids responsible for receptor binding but adds four amino-acid substitutions that resist enzymatic cleavage by dipeptidyl peptidase-IV (DPP-IV) and other serum proteases. The result is a peptide whose half-life extends from minutes to hours in the no-DAC version, or to days in the DAC version via albumin binding.

Longer receptor engagement means more GH pulses are amplified per dose. More GH pulses mean sustained hepatic IGF-1 production. This is a fundamentally different mechanism from recombinant human GH (rhGH), which suppresses endogenous GH feedback. CJC-1295 works within the feedback axis, so GH and IGF-1 are still subject to somatostatin counterregulation, which provides a partial ceiling on supraphysiologic elevation [2].

DAC vs. No-DAC: Why Formulation Changes the IGF-1 Response

The no-DAC version (often labeled "Modified GRF 1-29" at 503A compounding pharmacies) has a half-life of approximately 30 minutes. Administered subcutaneously two to three times daily, it produces discrete GH pulses that mirror the physiologic pattern. IGF-1 begins climbing within 48 to 72 hours of consistent dosing and reaches a new steady state in roughly 3 to 4 weeks.

The DAC-conjugated version has a terminal half-life of 6 to 8 days, producing a prolonged GH plateau rather than discrete pulses. Teichman et al. Reported that a single 2,000 mcg subcutaneous dose of CJC-1295 with DAC raised mean GH from approximately 1.3 ng/mL at baseline to a peak of 10.1 ng/mL, and IGF-1 rose 26 to 44% above baseline within two weeks [1]. Weekly dosing maintains this elevation continuously.

Clinicians ordering IGF-1 labs should document which formulation the patient is using. The two versions are not interchangeable, and their IGF-1 trajectories differ enough to affect monitoring intervals.

Magnitude of IGF-1 Increase: What the Data Show

The Teichman 2006 RCT enrolled 65 healthy adults (ages 21 to 61) and randomized them to single subcutaneous doses of CJC-1295 with DAC at 30, 60, 90, or 120 mcg/kg, or to placebo [1]. The key IGF-1 findings:

• At 60 mcg/kg: mean IGF-1 rose approximately 30% above baseline, sustained through day 14.
• At 120 mcg/kg: mean IGF-1 rose approximately 44% above baseline, with the trajectory still upward at the final observation point.
• Placebo group: no meaningful IGF-1 change (less than 3% fluctuation within normal diurnal variation).

The authors noted "statistically significant (P<0.0001) increases in mean IGF-1 concentrations" at all active doses, with the effect described as "prolonged, dose-dependent" [1].

Across observational data from compounding-pharmacy-based GH peptide programs (no-DAC formulations, typical doses of 100 to 300 mcg per injection given two to three times daily), the reported IGF-1 increases generally fall in the 30 to 90 ng/mL absolute range from baseline. The percentage rise depends heavily on the patient's starting IGF-1, which itself correlates with age, sex, and baseline GH axis function [3].

Why Starting IGF-1 Matters

A 45-year-old man with a baseline IGF-1 of 80 ng/mL (below the age-adjusted normal of approximately 100 to 210 ng/mL) has more room to rise before hitting the upper limit than a 30-year-old woman whose baseline is already 180 ng/mL. Clinicians at HealthRX evaluate baseline IGF-1 before initiating any GH secretagogue, because the starting value predicts both therapeutic headroom and the likelihood of hitting supraphysiologic levels.

The HealthRX GH Peptide Monitoring Framework stratifies patients into three tiers at baseline:

| Tier | Baseline IGF-1 | Starting Dose (No-DAC CJC-1295) | First Recheck | |------|---------------|----------------------------------|---------------| | Low (symptomatic deficiency) | <100 ng/mL | 100 mcg BID | 6 weeks | | Mid-normal | 100 to 180 ng/mL | 100 mcg BID or consider lower | 6 weeks | | High-normal | >180 ng/mL | Reassess indication | 4 weeks |

Patients in the high-normal tier rarely benefit from CJC-1295 and face a greater risk of pushing IGF-1 above the upper limit of normal (ULN), which is associated with increased IGF-1-driven cell proliferation signals [4].

Comparing CJC-1295 to Other GH Secretagogues

Ipamorelin, a selective GH secretagogue receptor (GHSR) agonist, is frequently co-administered with CJC-1295 (modified GRF) because the two act on different receptors and produce additive GH release. Bowers et al. Established the GHSR mechanism foundationally [5]. In combined protocols, IGF-1 rises are modestly larger than with either agent alone, typically 10 to 20% greater than CJC-1295 monotherapy at equivalent GH secretagogue doses. Serial IGF-1 monitoring becomes more important in combination because the additive GH stimulus makes supraphysiologic IGF-1 more likely.

Sermorelin, an older GHRH analogue using the native 1-29 sequence without DPP-IV-resistant substitutions, raises IGF-1 to a lesser degree for equivalent injection frequency due to its shorter functional half-life [6]. Patients switching from sermorelin to CJC-1295 (modified GRF) often see a further 15 to 25% IGF-1 increment.

Time Course: When IGF-1 Rises and When It Plateaus

Understanding the time course prevents both premature lab checks (before levels stabilize) and delayed detection of overshooting the target range.

No-DAC (Modified GRF 1-29) Time Course

With twice-daily subcutaneous dosing at 100 to 200 mcg per injection:

• Days 1 to 3: GH pulses amplify with each injection, but IGF-1 has not yet accumulated meaningfully above baseline. A day-3 IGF-1 is not clinically interpretable as a steady-state value.
• Days 5 to 14: IGF-1 begins climbing. Patients sometimes notice improved sleep quality and mild water retention during this window, consistent with rising GH/IGF-1 activity.
• Weeks 3 to 6: IGF-1 reaches or approaches its new steady state. The 6-week timepoint is the standard first monitoring draw.
• Week 12 and beyond: IGF-1 tends to remain stable if dosing is consistent. Annual or biannual rechecks are appropriate for patients on long-term therapy.

DAC-Conjugated CJC-1295 Time Course

Weekly dosing at 500 to 2,000 mcg (per the Teichman dose range) produces a faster initial IGF-1 rise because GH elevation is continuous rather than pulsatile:

• Day 5 to 7 post-first-dose: IGF-1 is already measurably above baseline in most patients.
• After second dose (day 14): Steady-state GH and IGF-1 are substantially established. A two-week IGF-1 check is reasonable with the DAC formulation.
• Ongoing: Monthly IGF-1 checks for the first three months, then quarterly if stable, is a widely used protocol among peptide prescribers.

Teichman et al. Explicitly noted that GH and IGF-1 remained elevated "for up to 14 days" after a single dose and that "weekly or biweekly administration could maintain elevated IGF-1 and GH concentrations," a finding that directly shaped modern weekly-dosing protocols [1].

Monitoring IGF-1 on CJC-1295: A Clinical Protocol

What to Measure and When

IGF-1 is the primary monitoring biomarker for CJC-1295 therapy. GH itself is not useful for routine monitoring because it pulses every 90 to 120 minutes, and a random serum GH reflects only a single transient moment. IGF-1 averages GH exposure over 24 to 48 hours, making it a stable, reproducible surrogate [3].

The American Association of Clinical Endocrinology (AACE) guidelines on GH therapy state that "serum IGF-1 is the primary biochemical marker used to monitor adequacy and safety of GH replacement" [7]. While those guidelines address rhGH rather than secretagogues specifically, the same hepatic IGF-1 production pathway applies, and most peptide-prescribing clinicians apply the same monitoring logic.

Minimum monitoring schedule for CJC-1295 (no-DAC, standard outpatient protocol):

1. Baseline IGF-1 before first injection.
2. Week 6 to 8 IGF-1 on stable dose. This is the dose-titration decision point.
3. Week 12 to 16 IGF-1 recheck after any dose adjustment.
4. Every 6 months on a stable, well-tolerated dose.

For the DAC formulation, compress the first recheck to week 2 to 3 given faster IGF-1 kinetics.

Target Range and Dose Adjustment Rules

The standard target is the age-adjusted mid-normal IGF-1 range. Most clinical laboratories provide age- and sex-stratified reference intervals. A common practical target used in peptide-prescribing practices is the 50th to 75th percentile for the patient's age and sex, which keeps IGF-1 within physiologic bounds while confirming pharmacologic activity.

If IGF-1 exceeds the ULN on two consecutive draws separated by at least four weeks, the appropriate response is a 25 to 50% dose reduction, not discontinuation. If IGF-1 remains above ULN after dose reduction, therapy should pause and the patient reassessed for endogenous GH axis changes or contributing factors (obesity, hypothyroidism, or testosterone changes that independently modulate IGF-1) [3].

If IGF-1 is below the lower limit of normal (LLN) at the week-6 check and the patient is tolerating injections correctly, a 25 to 50% dose increase or addition of a GHSR agonist (such as ipamorelin 200 mcg) is a reasonable next step.

Confounders That Change IGF-1 Independent of CJC-1295

Several variables shift IGF-1 and must be considered when interpreting labs:

• Nutritional status: Caloric restriction and protein deficiency reduce IGF-1 independent of GH. A patient losing weight on GLP-1 therapy concurrent with CJC-1295 may show blunted IGF-1 rise despite adequate GH secretion [8].
• Thyroid function: Hypothyroidism suppresses hepatic IGF-1 production. Undiagnosed or undertreated hypothyroidism can mask a therapeutic IGF-1 response.
• Testosterone and estrogen: Both androgens and estrogens modulate hepatic GH receptor sensitivity. Patients starting or stopping TRT or HRT concurrently will show IGF-1 fluctuations attributable to those changes, not CJC-1295 dose.
• Insulin resistance and obesity: Visceral adiposity blunts GH secretion and lowers baseline IGF-1. These patients may show a larger percentage rise from CJC-1295 because their starting point is lower, but they also have less predictable responses [2].
• Time of draw: IGF-1 is relatively stable across the day compared to GH, but morning fasting draws are standard practice for reproducibility. Confirm the patient drew labs fasted and in the morning when comparing serial results.

Safety Considerations: When High IGF-1 Becomes a Concern

Supraphysiologic IGF-1 and Cell Proliferation

Chronically elevated IGF-1 above the ULN is not a benign finding. The IGF-1 receptor activates PI3K-Akt-mTOR pathways that drive cell proliferation. Epidemiologic data associate high-normal to supraphysiologic IGF-1 with increased risk of colorectal, prostate, and breast cancer, though causality has not been established in interventional trials [4]. The FDA-approved prescribing information for somatropin (rhGH) includes a warning regarding neoplasia risk, which informed the clinical conservatism applied to IGF-1 target ranges for all GH-axis therapies [9].

CJC-1295 operates within endogenous feedback constraints, so the ceiling on IGF-1 is higher than zero but lower than with exogenous rhGH. Somatostatin release from the hypothalamus provides a partial brake. Even so, patients at doses above 300 mcg BID (no-DAC) or above 2,000 mcg weekly (DAC) can exceed the ULN, particularly younger patients with strong baseline GH axis function.

Acromegaly Is Extremely Unlikely but Not Zero-Risk

Acromegaly results from chronically supraphysiologic GH and IGF-1 over years. GH secretagogues operating within the feedback axis are considered low-risk for acromegaly because somatostatin suppression provides a ceiling. No published case reports of CJC-1295-induced acromegaly exist in the peer-reviewed literature as of this writing. The risk is considered theoretical but informs the rationale for periodic IGF-1 monitoring rather than indefinite unmonitored dosing.

Other Lab Values to Include at Baseline

IGF-1 is the primary marker, but a full baseline panel for CJC-1295 therapy should include:

• Fasting glucose and HbA1c (GH is counter-regulatory to insulin; elevated GH can worsen insulin sensitivity transiently) [2]
• Thyroid panel (TSH, free T4)
• Complete metabolic panel
• Total and free testosterone (in men), estradiol (in women) for confounding assessment
• Cortisol (AM fasting) if adrenal insufficiency is suspected, because GH secretagogues can unmask central adrenal insufficiency in rare cases

The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults explicitly recommends monitoring glucose and HbA1c during GH-axis therapy given the transient insulin counter-regulation effect [3].

Practical Injection Timing and Its Effect on IGF-1 Labs

Injection timing relative to the lab draw does not meaningfully affect IGF-1 the way it affects GH. IGF-1 has a half-life of approximately 12 to 15 hours when bound to IGF-binding protein-3 (IGFBP-3), meaning it buffers short-term GH fluctuations. A patient who injected CJC-1295 six hours before the draw versus 18 hours before will show nearly identical IGF-1 values [3].

For the no-DAC formulation, the standard instruction is to take the morning blood draw at a consistent time, regardless of when the most recent injection occurred. The 6-week timepoint captures accumulated IGF-1 production, not a single-dose response.

For the DAC formulation, draw IGF-1 midway between injections (for example, day 3 or 4 after a weekly injection) to avoid capturing the acute post-injection peak, which may be transient and not representative of average exposure.